MiNK Therapeutics, Inc. (INKT) compared with its closest peers (PROK, CSBR, CRDF, EXOZ, INMB). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| ProKidney Corp. (PROK) | $99.70M | -29.8 |
| Champions Oncology, Inc. (CSBR) | $70.30M | 17.6 |
| Cardiff Oncology, Inc. (CRDF) | $68.47M | -4.1 |
| eXoZymes, Inc. (EXOZ) | $68.45M | -9.7 |
| INmune Bio, Inc. (INMB) | $63.83M | -0.8 |
| ImageneBio Inc (IMA) | $63.34M | -0.7 |
| Instil Bio, Inc. (TIL) | $51.81M | -1.0 |
| Scilex Holding Company (SCLX) | $48.07M | -0.3 |
| Metagenomi, Inc. Common Stock (MGX) | $46.09M | -0.7 |
| Aligos Therapeutics, Inc. (ALGS) | $41.03M | -3.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
INKT overview · INKT earnings · INKT financials · INKT KPIs · INKT investor relations · INKT ownership · INKT filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.